Use EEG microstates to study the mechanism of reaction inhibition impairment in adolescent patients with depression.

Study on the mechanism of reaction inhibition impairment in adolescent patients with depression based on EEG microstates.

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2500108602

Enrollment

Unknown

Registered

2025-09-02

Start date

2025-01-01

Completion date

Unknown

Last updated

2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depressive Disorders

Interventions

Healthy participants control group:None

Depression patients group:None

Eligibility

Sex/Gender

All

Age

14 Years to 35 Years

Inclusion criteria

Inclusion criteria: Depression patients group: 1. Adolescents aged 14–35 years with first-episode, untreated major depressive disorder; 2. Montgomery-Åsberg Depression Rating Scale (MADRS) score >= 12; 3. 24-item Hamilton Depression Rating Scale (HAMD-24) score >= 8; 4. No history of comorbid psychiatric disorders (e.g., epilepsy, obsessive-compulsive disorder, post-traumatic stress disorder, social anxiety disorder); 5. No history of dependence on psychotropic medications; 6. No history of organic brain diseases; 7. Absence of severe somatic illnesses and no comorbid psychiatric conditions; 8. No acute/chronic infections, trauma, inflammation, fever, or allergic history within the past 2 weeks; 9. No history of alcohol or substance abuse; 10. Right-handed. Healthy participants group: 1. Screened negative for all psychiatric disorders via standardized questionnaires; 2. Aged 14–35 years, regardless of sex; 3. Matched to the depression group for sex and educational level; 4. Voluntarily participated and provided written informed consent.

Exclusion criteria

Exclusion criteria: Depression patients group: 1. Montgomery-Åsberg Depression Rating Scale (MADRS) score < 12; 2. 24-item Hamilton Depression Rating Scale (HAMD-24) score < 9; 3. History of comorbid psychiatric disorders; 4. Prior exposure to psychotropic medications for psychiatric treatment; 5. Refusal to provide written informed consent for the study. Healthy participants group: 1. Presence of organic brain diseases; 2.Current severe somatic illness, substance dependence, or psychotic symptoms; 3. Use of cognition-impairing medications within the past month; 4. Alcohol or substance dependence; 5. Intellectual disability precluding completion of study assessments.

Design outcomes

Primary

Measure	Time frame
Go/NoGo Test Score;EEG Microstates;Cognitive Function;Montgomery-sberg Depression Rating Scale (MADRS) score;Hamilton Depression Rating Scale (HAMD-24) scores;	—

Countries

China

Contacts

Public ContactLi Mengqian

The first affiliated hostipal of nanchang university

limengqian@126.com+86 791 88692280

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026